Daiichi Sankyo Rolls Out Lung, Breast Cancer Data for HER3-Directed ADC

Daiichi Sankyo on March 20 released the latest data from two early-stage global studies for its HER3-targeted antibody-drug conjugate (ADC) patritumab deruxtecan (HER3-DXd) for the treatment of EGFR-mutated lung cancer and HER3-expressing breast cancer. The latest data covered updated results...read more